Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6503
    +0.0014 (+0.22%)
     

  • OIL

    82.96
    -0.40 (-0.48%)
     

  • GOLD

    2,335.00
    -7.10 (-0.30%)
     

  • Bitcoin AUD

    98,952.44
    -3,372.24 (-3.30%)
     

  • CMC Crypto 200

    1,388.38
    -35.72 (-2.51%)
     

  • AUD/EUR

    0.6073
    +0.0017 (+0.28%)
     

  • AUD/NZD

    1.0949
    +0.0019 (+0.17%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,528.72
    +57.25 (+0.33%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,474.05
    -29.64 (-0.08%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

Chimerix, Inc.
·1-min read
Chimerix, Inc.
Chimerix, Inc.

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PT in San Francisco, CA.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

ADVERTISEMENT

CONTACTS: 

Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Nick Lamplough / Dan Moore / Tanner Kaufman
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449